MassBiologics and AbCellera partner to discover fully human antibodies against drug-resistant bacteria.
MassBiologics Discovery for Lyme Disease PrEP.
World's first fast-acting Anti-Rabies drug will be launched in India this year.
Researchers isolate Ebola antibodies in quest for vaccine, treatment.
MassBiologics discovery is nearing launch in India.
Local Delegation tours MassBiologics SouthCoast Facility.
MassBiologics collaborator AbCellera Announces their Success.
Grifols Obtains Exclusive Rights to Market and Distribute MassBiologics' Td Vaccine in US.
MassBiologics now fully manufacturing vaccine at Mattapan facility.
MassBiologics tests new way to stave off Lyme Disease: Boston Magazine
MassBiologics: Cementing Massachusetts' Status as Life Sciences Hub for over 120 Years
Gene therapy startup Voyager announces manufacturing partnership with MassBiologics
Voyager Therapeutics and MassBiologics Announce Strategic Collaboration for Viral Vector Manufacturing
Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab
MassBiologics scientist publishes guide to large scale mammalian cell culture equipment
FDA grants orphan drug status to MassBiologics for MBL-HCV-1
MassBiologics receives UMASS S&T award
MassBiologics receives UMASS President award
MassBiologics Donates Over One Million Doses of Tetanus and Diphtheria Vaccine to Global NGO Project HOPE
MassBiologics CEO, Mark Klempner discusses Lyme disease
Project Hope Update - MassBiologics noted amongst philanthropic donors
Merck study reveals mechanism of action for anti-C.difficile MAb developed at MassBiologics
Mechanism of action and epitopes of the C. difficile toxin B neutralizing antibody bezlotoxumab
Tufts study points to site of action for MassBiologics developed anti-C.difficile antibodies
This is an official Page of the University of Massachusetts Medical School
MassBiologics 460 Walk Hill Street Boston, MA 02126
Questions or Comments?